Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes
Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes In low-risk myelodysplastic syndrome (LR-MDS), erythropoietin (EPO) is widely used for the treatment of chronic anemia. However, initial response to EPO has time-limited effects. Luspatercept reduces red blood cell transfusion dependence in LR-MDS patients. Here, we investigated the molecular action of luspatercept (RAP-536) […]